{"id":9088,"date":"2023-04-14T15:54:07","date_gmt":"2023-04-14T13:54:07","guid":{"rendered":"https:\/\/semmelweis.hu\/bioinformatika\/?p=9088"},"modified":"2023-04-28T15:02:39","modified_gmt":"2023-04-28T13:02:39","slug":"megjelent-kovacs-szonja-anna-cikke-az-acta-pharmacologica-sinica-folyoiratban","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/bioinformatika\/megjelent-kovacs-szonja-anna-cikke-az-acta-pharmacologica-sinica-folyoiratban\/","title":{"rendered":"Megjelent Kov\u00e1cs Szonja Anna cikke az Acta Pharmacologica Sinica foly\u00f3iratban"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-9092 alignleft\" src=\"https:\/\/semmelweis.hu\/bioinformatika\/files\/2023\/04\/Acta-Pharmacologica-Sinica1500_386-400x103.jpg\" alt=\"\" width=\"400\" height=\"103\" srcset=\"https:\/\/semmelweis.hu\/bioinformatika\/files\/2023\/04\/Acta-Pharmacologica-Sinica1500_386-400x103.jpg 400w, https:\/\/semmelweis.hu\/bioinformatika\/files\/2023\/04\/Acta-Pharmacologica-Sinica1500_386-1024x264.jpg 1024w, https:\/\/semmelweis.hu\/bioinformatika\/files\/2023\/04\/Acta-Pharmacologica-Sinica1500_386-768x198.jpg 768w, https:\/\/semmelweis.hu\/bioinformatika\/files\/2023\/04\/Acta-Pharmacologica-Sinica1500_386-753x194.jpg 753w, https:\/\/semmelweis.hu\/bioinformatika\/files\/2023\/04\/Acta-Pharmacologica-Sinica1500_386.jpg 1500w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><span style=\"font-size: 1rem\">Kov\u00e1cs Szonja Anna, Dr. Fekete J\u00e1nos Tibor \u00e9s Dr. Gy\u0151rffy Bal\u00e1zs cikke 2023. \u00e1prilis 13.-\u00e1n jelent meg az Acta Pharmacologica Sinica \u00fajs\u00e1gban (IF=7,165). A tanulm\u00e1nyban a szerz\u0151k egy g\u00e9nexpresszi\u00f3s \u00e9s klinikai adatokb\u00f3l \u00e1ll\u00f3 adatb\u00e1zist hoztak l\u00e9tre az anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab) \u00e9s anti-CTLA-4 (ipilimumab) immunter\u00e1pi\u00e1kra adott ter\u00e1pi\u00e1s v\u00e1lasz biomarkereinek azonos\u00edt\u00e1s\u00e1hoz. Ehhez ROC-anal\u00edzist \u00e9s Mann-Whitney-tesztet v\u00e9geztek. Az adatb\u00e1zis 1434 tumorsz\u00f6vetmint\u00e1t tartalmaz 19 tanulm\u00e1nyb\u00f3l az al\u00e1bbi tumort\u00edpusokb\u00f3l: melanoma, nyel\u0151cs\u0151-, gyomor-, fej-nyak-, t\u00fcd\u0151- \u00e9s urotheli\u00e1lis daganatok. Az anti-PD-1 rezisztenci\u00e1val \u00f6sszef\u00fcgg\u00e9sbe hozhat\u00f3 leger\u0151sebb, gy\u00f3gyszeresen c\u00e9lozhat\u00f3 g\u00e9njel\u00f6ltek a SPIN1 (AUC=0,682, P=9,1E-12), SRC (AUC=0,667, P=5,9E-10), SETD7 (AUC=0. 663, P=1,0E-09), FGFR3 (AUC=0,657, P=3,7E-09), YAP1 (AUC=0,655, P=6,0E-09), TEAD3 (AUC=0,649, P=4,1E-08) \u00e9s BCL2 (AUC=0,634, P=9,7E-08) voltak. Az anti-CTLA-4 kezel\u00e9si kohorszban a BLCAP (AUC=0,735, P=2,1E-06) volt a leg\u00edg\u00e9retesebb g\u00e9njel\u00f6lt. Az anti-PD-L1 csoportban nem tal\u00e1ltak ter\u00e1pi\u00e1san relev\u00e1ns c\u00e9lpontot. Az \u00faj biomarkerjel\u00f6ltek tov\u00e1bbi elemz\u00e9s\u00e9hez \u00e9s valid\u00e1l\u00e1s\u00e1hoz webes platformot hoztak l\u00e9tre, amely a <\/span><a href=\"https:\/\/www.rocplot.com\/immune\">https:\/\/www.rocplot.com\/immune<\/a><span style=\"font-size: 1rem\"> c\u00edmen \u00e9rhet\u0151 el.<\/span><\/p>\n<p>A cikk<a href=\"https:\/\/www.nature.com\/articles\/s41401-023-01079-6\"> ide kattintva<\/a> \u00e9rhet\u0151 el.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kov\u00e1cs Szonja Anna, Dr. Fekete J\u00e1nos Tibor \u00e9s Dr. Gy\u0151rffy Bal\u00e1zs cikke 2023. \u00e1prilis 13.-\u00e1n jelent meg az Acta Pharmacologica Sinica \u00fajs\u00e1gban (IF=7,165). A tanulm\u00e1nyban a szerz\u0151k egy g\u00e9nexpresszi\u00f3s \u00e9s klinikai adatokb\u00f3l \u00e1ll\u00f3 adatb\u00e1zist hoztak l\u00e9tre az anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab) \u00e9s anti-CTLA-4 (ipilimumab) immunter\u00e1pi\u00e1kra adott ter\u00e1pi\u00e1s v\u00e1lasz biomarkereinek azonos\u00edt\u00e1s\u00e1hoz. Ehhez ROC-anal\u00edzist \u00e9s &hellip;<\/p>\n","protected":false},"author":102018,"featured_media":9104,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-9088","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hirek"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/posts\/9088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/users\/102018"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/comments?post=9088"}],"version-history":[{"count":7,"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/posts\/9088\/revisions"}],"predecessor-version":[{"id":9167,"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/posts\/9088\/revisions\/9167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/media\/9104"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/media?parent=9088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/categories?post=9088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/bioinformatika\/wp-json\/wp\/v2\/tags?post=9088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}